DOI QR코드

DOI QR Code

A Case of Acute Appendicitis in a Patient with Methimazole-Induced Agranulocytosis

그레이브스병에서 메티마졸 투여 후 발생한 무과립구증과 급성충수염

  • Hong, A Ram (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Park, Kyeong Seon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Jo, Yong Suk (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Park, Do Joon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Park, Young Joo (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Jung Hee (Department of Internal Medicine, Seoul National University College of Medicine)
  • 홍아람 (서울대학교 의과대학 내과학교실) ;
  • 박경선 (서울대학교 의과대학 내과학교실) ;
  • 조용숙 (서울대학교 의과대학 내과학교실) ;
  • 박도준 (서울대학교 의과대학 내과학교실) ;
  • 박영주 (서울대학교 의과대학 내과학교실) ;
  • 김정희 (서울대학교 의과대학 내과학교실)
  • Received : 2013.05.09
  • Accepted : 2013.08.26
  • Published : 2014.02.01

Abstract

Agranulocytosis is a rare, but life-threatening, adverse effect of methimazole, which usually manifests as an upper respiratory infection. Agranulocytosis together with acute appendicitis is especially rare in patients with Graves' disease taking methimazole. A 44-year-old woman presented to our hospital with abdominal pain and a fever. She had been taking methimazole and propranolol for Graves' disease for the previous 8 weeks. Her symptoms were compatible with acute appendicitis. Computed tomography of the abdomen revealed acute appendicitis with impending rupture. However, the circulating absolute neutrophil count was $10/mm^3$. We managed her with antibiotics and granulocyte colony stimulating factor rather than with emergency surgery. The thyrotoxicosis was treated with intravenous contrast medium while fasting, followed by Lugol's solution and lithium. After recovering from the neutropenia, she underwent a total thyroidectomy combined with an appendectomy. Here, we report a patient with Graves' disease who developed methimazole-induced agranulocytosis presenting as acute appendicitis.

무과립구증은 메티마졸을 복용하는 환자에서 드물게 발생하나 치명적인 부작용으로서 대부분 상기도 감염의 형태로 발현한다. 그레이브스병으로 메티마졸을 복용하던 환자에서 무과립구증이 급성충수염으로 발현한 증례는 보고된바 없다. 본 저자들은 그레이브스병으로 메티마졸을 복용하던 중 발생한 무과립구증이 드물게 급성충수염으로 발현한 환자에서 적절한 내과적 치료 및 수술적 치료 후 양호한 경과를 확인하였기에 문헌고찰과 함께 보고하는 바이다.

Keywords

References

  1. Cooper DS. Antithyroid drugs. N Engl J Med 1984;311:1353-1362. https://doi.org/10.1056/NEJM198411223112106
  2. Jeong GH, Kim SK, Myung DS, et al. Agranulocytosis due to secondary exposure to antithyroid drugs in a relapsed Graves' disease patient. Korean J Med 2008;75:362-366.
  3. Ryan ME, Morrissey JF. Typhlitis complicating methimazole-induced agranulocytosis. Gastrointest Endosc 1983;29:299-302. https://doi.org/10.1016/S0016-5107(83)72639-8
  4. Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 2009;19:559-563. https://doi.org/10.1089/thy.2008.0364
  5. Urbach DR, Rotstein OD. Typhilitis. Can J Surg 1999;42:415-419.
  6. Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med 2012;172:153-159. https://doi.org/10.1001/archinternmed.2011.677
  7. Streetman DD, Khanderia U. Diagnosis and treatment of Graves disease. Ann Pharmacother 2003;37:1100-1109. https://doi.org/10.1345/aph.1C299
  8. Pearce EN, Braverman LE. Hyperthyroidism: advantages and disadvantages of medical therapy. Surg Clin North Am 2004;84:833-847. https://doi.org/10.1016/j.suc.2004.01.007
  9. Salama A, Schutz B, Kiefel V, Breithaupt H, Mueller-Eckhardt C. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 1989;72:127-132. https://doi.org/10.1111/j.1365-2141.1989.tb07672.x
  10. Peralta FG, Sanchez MB, Roiz MP, Pena MA, Tejero MA, Arjona R. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam. Clin Infect Dis 2003;37:1568-1572. https://doi.org/10.1086/379519